Market Research

France Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online prov

Best Price Guarantee Length Publisher Published Date SKU
from $2,670 70 Pages Allied Market Research May, 2023 ALMR18790414
Best Price Guarantee
Price from $2,670
Length 70 Pages
Publisher Allied Market Research
Published Date May, 2023
SKU ALMR18790414

France Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Opportunity Analysis and Industry Forecast, 2023-2032


The France myasthenia gravis treatment market is anticipated to witness significant growth due to presence of massive pool of health-conscious consumers during the forecast period. Other major factors driving the growth of market are increase in prevalence of myasthenia gravis and rise in awareness regarding early diagnosis & adoption of novel treatment options for myasthenia gravis.

Further, the myasthenia gravis treatment market is expected to witness significant growth owing to rise in focus of pharmaceutical companies on the development of novel drugs for the treatment of the disease. In addition, several drugs, including monoclonal antibodies and immunosuppressants, are being developed & tested for their efficacy in treating myasthenia gravis. Moreover, increase in investment in R&D by pharmaceutical companies is expected to intensify the market growth. Furthermore, rise in awareness about myasthenia gravis among patients & healthcare professionals is contributing to rise in demand for its treatments. Further, as more people are gaining awareness regarding the symptoms & risks associated with myasthenia gravis, they are opting for early diagnosis & treatment.

Moreover, government initiatives to improve healthcare infrastructure & increase awareness about myasthenia gravis are driving the market growth. The market growth is further expected to be driven due to the availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of autoimmune diseases, and surge in demand for novel drugs for the management of myasthenia gravis. In addition, various organizations along with the government are counseling people regarding autoimmune diseases. Furthermore, numerous animations through health apps to educate people regarding myasthenia gravis & usage of medications have contributed toward the market growth. Further, rise in demand for effective intravenous immunoglobulin and monoclonal antibodies is expected to strengthen the development of the market. Moreover, increase in promotional activities by manufacturers is expected to fuel the market growth in the near future.

However, the myasthenia gravis treatment market is challenged by several restraints. The major restraint for the growth of the France myasthenia gravis treatment market are the side effects associated with the drugs used for the treatment of the disease. In addition, drugs such as corticosteroids and immunosuppressants are associated with several side effects, including increased risk of infection, weight gain, mood changes, & gastrointestinal problems, which can impact patient compliance further hampering the market growth. Moreover, the outbreak of COVID-19 has disrupted workflows in the healthcare sector of the France. The delay in diagnosis & treatment of myasthenia gravis during the pandemic had a significant impact on patient outcomes. During that time, patients with non-emergency conditions such as myasthenia gravis were unable to receive timely medical attention. This delay in diagnosis & treatment has led to disease progression and worsened symptoms, impacting the quality of life of myasthenia gravis patients.

Moreover, the pandemic disrupted the supply chains of drugs & medical devices in the France market, leading to shortages & delays in delivery of myasthenia gravis treatments. In addition, companies operating in the myasthenia gravis treatment market were impacted financially by the pandemic, with revenue growth being limited owing to supply chain issues. It has further increased the risk of myasthenic crisis, respiratory failure, and permanent pulmonary damage in myasthenia gravis patients due to their suppressed immune systems.

The myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin, and others. By age group, the market is segregated into below 55 years and above 55 years. Depending on the distribution channel, the market is divided into hospital pharmacies, drug stores, retail pharmacies & online providers.

Key players in the France myasthenia gravis treatment market are Sanofi, Merck KGaA, Mylan, Caremark, UCB Pharma, Teva Pharmaceuticals, Novartis, Abbott Laboratories, Eli Lilly, OBS Medical.

Key Benefits for Stakeholders

The report highlights the market analysis based on current trends and future estimations.

It analyzes the key strategies adopted by major market players in the France myasthenia gravis treatment market.

The study assesses and ranks the top factors that are expected to impact the growth of the France myasthenia gravis treatment market.

It identifies the top investment pockets in the market.

Top player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the France myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Age group

Below 55 years
Above 55 years

By Drug class

Monoclonal antibodies
Intravenous immunoglobulin
Others

By Distribution channel

Hospital pharmacies
Drug store and retail pharmacies
Online providers

Key Market Players

Sanofi
Merck KGaA
Mylan
Caremark
UCB Pharma
Teva Pharmaceuticals
Novartis
Abbott Laboratories
Eli Lilly
OBS Medical

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 


CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size and Forecast, By Drug class
4.2. Monoclonal antibodies
4.3. Intravenous immunoglobulin
4.4. Others
CHAPTER 5: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market Size and Forecast, By Age group
5.2. Below 55 years
5.3. Above 55 years
CHAPTER 6: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market Size and Forecast, By Distribution channel
6.2. Hospital pharmacies
6.3. Drug store and retail pharmacies
6.4. Online providers
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Company 1
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Company 2
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Company 3
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Company 4
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Company 5
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Company 6
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Company 7
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Company 8
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Company 9
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Company 10
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 03. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 04. COMPANY 1: KEY EXECUTIVES
TABLE 05. COMPANY 1: COMPANY SNAPSHOT
TABLE 06. COMPANY 1: OPERATING SEGMENTS
TABLE 07. COMPANY 1: PRODUCT PORTFOLIO
TABLE 08. COMPANY 1: KEY STRATERGIES
TABLE 09. COMPANY 2: KEY EXECUTIVES
TABLE 10. COMPANY 2: COMPANY SNAPSHOT
TABLE 11. COMPANY 2: OPERATING SEGMENTS
TABLE 12. COMPANY 2: PRODUCT PORTFOLIO
TABLE 13. COMPANY 2: KEY STRATERGIES
TABLE 14. COMPANY 3: KEY EXECUTIVES
TABLE 15. COMPANY 3: COMPANY SNAPSHOT
TABLE 16. COMPANY 3: OPERATING SEGMENTS
TABLE 17. COMPANY 3: PRODUCT PORTFOLIO
TABLE 18. COMPANY 3: KEY STRATERGIES
TABLE 19. COMPANY 4: KEY EXECUTIVES
TABLE 20. COMPANY 4: COMPANY SNAPSHOT
TABLE 21. COMPANY 4: OPERATING SEGMENTS
TABLE 22. COMPANY 4: PRODUCT PORTFOLIO
TABLE 23. COMPANY 4: KEY STRATERGIES
TABLE 24. COMPANY 5: KEY EXECUTIVES
TABLE 25. COMPANY 5: COMPANY SNAPSHOT
TABLE 26. COMPANY 5: OPERATING SEGMENTS
TABLE 27. COMPANY 5: PRODUCT PORTFOLIO
TABLE 28. COMPANY 5: KEY STRATERGIES
TABLE 29. COMPANY 6: KEY EXECUTIVES
TABLE 30. COMPANY 6: COMPANY SNAPSHOT
TABLE 31. COMPANY 6: OPERATING SEGMENTS
TABLE 32. COMPANY 6: PRODUCT PORTFOLIO
TABLE 33. COMPANY 6: KEY STRATERGIES
TABLE 34. COMPANY 7: KEY EXECUTIVES
TABLE 35. COMPANY 7: COMPANY SNAPSHOT
TABLE 36. COMPANY 7: OPERATING SEGMENTS
TABLE 37. COMPANY 7: PRODUCT PORTFOLIO
TABLE 38. COMPANY 7: KEY STRATERGIES
TABLE 39. COMPANY 8: KEY EXECUTIVES
TABLE 40. COMPANY 8: COMPANY SNAPSHOT
TABLE 41. COMPANY 8: OPERATING SEGMENTS
TABLE 42. COMPANY 8: PRODUCT PORTFOLIO
TABLE 43. COMPANY 8: KEY STRATERGIES
TABLE 44. COMPANY 9: KEY EXECUTIVES
TABLE 45. COMPANY 9: COMPANY SNAPSHOT
TABLE 46. COMPANY 9: OPERATING SEGMENTS
TABLE 47. COMPANY 9: PRODUCT PORTFOLIO
TABLE 48. COMPANY 9: KEY STRATERGIES
TABLE 49. COMPANY 10: KEY EXECUTIVES
TABLE 50. COMPANY 10: COMPANY SNAPSHOT
TABLE 51. COMPANY 10: OPERATING SEGMENTS
TABLE 52. COMPANY 10: PRODUCT PORTFOLIO
TABLE 53. COMPANY 10: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN FRANCE MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 10. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET,BY DRUG CLASS, 2022 ($MILLION)
FIGURE 11. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET,BY AGE GROUP, 2022 ($MILLION)
FIGURE 12. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
FIGURE 21. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
FIGURE 24. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
FIGURE 27. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
FIGURE 30. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
FIGURE 33. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
FIGURE 36. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
FIGURE 39. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
FIGURE 42. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
FIGURE 45. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
FIGURE 48. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

$3,570
$2,670
$4,560
$5,550

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings